Evidence map›Paper›PMID 20119865›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2010

Are healthcare economics a factor behind European MRSA rates?

M A Borg

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

M A BorgInfection Control Unit, Mater Dei Hospital, Msida, Malta. michael.a.borg@gov.mt

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study assessed the relationship between meticillin-resistant Staphylococcus aureus (MRSA) prevalence in 26 European countries with two key socioeconomic parameters, namely, gross domestic product per capita (GDP) and infant mortality rate (IMR). Whilst no significant relationship was identified between MRSA and GDP (Spearman correlation: -0.387; 95% confidence interval [CI]: -0.674 to 0.000; p = 0.0528), a significant correlation was evident between MRSA and IMR (Spearman correlation: 0.545; 95% CI: 0.208 to 0.766; p = 0.005). The elimination of a widely outlying data point retained significance. Various studies have shown IMR to be a good marker of healthcare expenditure and it is, therefore, reasonable to postulate that one possible factor in the multi-factorial epidemiology of MRSA in Europe is the level and effectiveness of healthcare expenditure within the individual countries.

Indexed as

Cost of IllnessEuropeHealth Care CostsHumansInfantInfant MortalityInfant, NewbornMethicillin-Resistant Staphylococcus aureusPrevalenceStaphylococcal Infections

Identifiers

PMID20119865

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.